Source: Eur Respir J 2010; 36: 1483-1485
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Ilsar R., Levitt J., Ng M.K.C., Kritharides L., Adams M.R., Celermajer D.S.. Bosentan and improved pulmonary endothelial function in pulmonary arterial hypertension. Eur Respir J 2010; 36: 1483-1485

Member's Comments

No comment yet.

Related content which might interest you: MnTBAP reduces pulmonary vascular remodeling in experimental pulmonary arterial hypertension Source: International Congress 2019 – Pulmonary hypertension: novelties from the bench Year: 2019 Apelin improves cardiac output in patients with pulmonary arterial hypertension Source: International Congress 2015 – Pulmonary hypertension: novel clinical insights Year: 2015 Single arterial occlusion to locate resistance in patients with pulmonary hypertension Source: Eur Respir J 2003; 21: 31-36 Year: 2003 Improvement of exercise capacity in monocrotaline induced pulmonary hypertension by the phosphodiesterase inhibitor Vardenafil Source: Annual Congress 2006 - Signalisation in the pulmonary vasculature: new pathways and wrong signals Year: 2006 Endothelium in pulmonary arterial hypertension Source: Annual Congress 2007 - Role of the endothelium in pulmonary function and disease Year: 2007 Long-term efficacy of bosentan in treatment of pulmonary arterial hypertension in children Source: Eur Respir J 2011; 37: 70-77 Year: 2011 Impact on survival of pulmonary function abnormalities in pulmonary arterial hypertension Source: Annual Congress 2009 - Pulmonary hypertension Year: 2009 Beyond arterial remodelling: pulmonary venous and cardiac involvement in patients with systemic sclerosis-associated pulmonary arterial hypertension Source: Eur Respir J 2010; 35: 6-8 Year: 2010 ACE2 activation improves pulmonary endothelial function and attenuates monocrotaline-induced pulmonary hypertension Source: Annual Congress 2011 - Treatment of human pulmonary hypertension Year: 2011 Bosentan does not improve pulmonary hypertension and lung remodeling in heart failure Source: Eur Respir J 2011; 37: 578-586 Year: 2011 The vascular bed in COPD: pulmonary hypertension and pulmonary vascular alterations Source: Eur Respir Rev 2014; 23: 350-355 Year: 2014 Exercise limitation in idiopathic pulmonary arterial hypertension (IPAH): there‘s more to it than just the pulmonary circulation Source: Eur Respir J 2005; 26: Suppl. 49, 560s Year: 2005 The transpulmonary pressure gradient for the diagnosis of pulmonary vascular disease Source: Eur Respir J 2013; 41: 217-223 Year: 2013 Effect of riociguat on pulmonary arterial compliance in patients with pulmonary arterial hypertension (PAH) in the RESPITE study Source: International Congress 2017 – New insights into pulmonary hypertension from recent trials Year: 2017 Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil Source: Eur Respir J 2006; 28: 1195-1203 Year: 2006 Iron deficiency in pulmonary arterial hypertension: a potential therapeutic target Source: Eur Respir J 2011; 38: 1453-1460 Year: 2011 Pulmonary vascular distensibility in pulmonary hypertension due to left heart disease Source: International Congress 2018 – Pulmonary hypertension: right ventricle function, haemodynamics and exercise Year: 2018 Endothelial NO and its pathophysiologic regulation Source: Annual Congress 2007 - Role of the endothelium in pulmonary function and disease Year: 2007 Assessment of platelet dysfunction in patients with pulmonary arterial hypertension Source: International Congress 2016 – Pulmonary hypertension: the clinic I Year: 2016